The MRP rates on the drug indicated were significantly higher than the ceiling price fixed for the product under the Drugs (Prices Control) Order, 2013 by National Pharmaceutical Pricing Authority (c), the price control regulatory authority
HC bench said it wanted to ascertain whether the Union government was ensuring an "equitable distribution" of drugs based on the number of active cases of Mucormycosis in each state
